Long-Term Investor Stock Analysis of Amgen (AMGN)Read More »
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Long-Term Investor Stock Analysis of Amgen (AMGN)
Views: 411 Date: 2025-09-18 Amgen is one of the world’s largest biotechnology companies. It develops, manufactures, and markets human therapeutics, with a focus on oncology, inflammation, cardiovascular disease, bone health, nephrology, and rare diseases. Its key drugs include Enbrel, Prolia, Repatha, and Otezla, supplemented by a growing biosimilars portfolio. The company generates ~$35 B in annual revenue with high margins and global reach. Business Model Simplicity and Sustainability The model—developing biologics, protecting them with patents, and leveraging a large-scale manufacturing and distribution network—is straightforward for experienced investors. Sustainability is moderate: patent cliffs and biosimilar competition require continuous innovation, but Amgen …
